BNP as a marker of the heart failure in the treatment of imatinib mesylate.

Abstract

Since its introduction 6 years ago, imatinib mesylate, a selective tyrosine kinase inhibitor, has been a phenomenon in treating chronic myelogenous leukemia (CML) with remarkably superior cytogenetic and molecular response rates at all stages of CML followed by longer progression free survival. Despite its extraordinarily high efficacy, adverse effects of imatinib mesylate such as edema, liver toxicity and fluid retention syndromes have been reported. Here we, for the first time, report development of heart failure in patients on imatinib mesylate medication and the possibility of brain natriuretic peptide (BNP) as a potential diagnostic (or predicting) marker for heart failure. Since plasma BNP levels in the two patients were exceptionally high, we then explored the possibility of genetic association of BNP with the development of heart failure to find no positive association.

• Authors: Yeon Hee Park, Hae Jeong Park, Bong-Seog Kim, Eunyoung Ha, Kyung Hee Jung, Seo Hyun Yoon, Sung Vin Yim, Joo-Ho Chung
• Journal: Cancer letters (Cancer Lett) Vol. 243 Issue 1 Pg. 16-22 (Nov 08 2006) ISSN: 0304-3835 [Print] Ireland
• PMID: 16388897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzamides
• Biomarkers, Tumor
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Natriuretic Peptide, Brain
• Imatinib Mesylate

Topics

• Adult
• Aged
• Alleles
• Base Sequence
• Benzamides
• Biomarkers, Tumor (blood, genetics)
• DNA Mutational Analysis
• Diarrhea (chemically induced)
• Edema (chemically induced)
• Exanthema (chemically induced)
• Female
• Gastrointestinal Stromal Tumors (drug therapy, genetics)
• Gene Frequency
• Genotype
• Heart Failure (blood, chemically induced, diagnosis)
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics)
• Male
• Middle Aged
• Natriuretic Peptide, Brain (blood, genetics)
• Piperazines (adverse effects, therapeutic use)
• Polymorphism, Single Nucleotide (genetics)
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)
• Treatment Outcome